1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
3
|
Cooke SL and Brenton JD: Evolution of
platinum resistance in high-grade serous ovarian cancer. Lancet
Oncol. 12:1169–1174. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Miller DS, Blessing JA, Krasner CN, Mannel
RS, Hanjani P, Pearl ML, Waggoner SE and Boardman CH: Phase II
evaluation of pemetrexed in the treatment of recurrent or
persistent platinum-resistant ovarian or primary peritoneal
carcinoma: A study of the Gynecologic Oncology Group. J Clin Oncol.
27:2686–2691. 2009. View Article : Google Scholar : PubMed/NCBI
|
5
|
Pfisterer J and Ledermann JA: Management
of platinum-sensitive recurrent ovarian cancer. Semin Oncol. 33 2
Suppl:S12–S16. 2006. View Article : Google Scholar : PubMed/NCBI
|
6
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
7
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
8
|
Arcangeli A, Crociani O, Lastraioli E,
Masi A, Pillozzi S and Becchetti A: Targeting ion channels in
cancer: A novel frontier in antineoplastic therapy. Curr Med Chem.
16:66–93. 2009. View Article : Google Scholar : PubMed/NCBI
|
9
|
Cuddapah VA and Sontheimer H: Ion channels
and transporters [corrected] in cancer. 2. Ion channels and the
control of cancer cell migration. Am J Physiol Cell Physiol.
301:C541–C549. 2011. View Article : Google Scholar : PubMed/NCBI
|
10
|
Prevarskaya N, Skryma R and Shuba Y: Ion
channels and the hallmarks of cancer. Trends Mol Med. 16:107–121.
2010. View Article : Google Scholar : PubMed/NCBI
|
11
|
D'Amico M, Gasparoli L and Arcangeli A:
Potassium channels: Novel emerging biomarkers and targets for
therapy in cancer. Recent Pat Anticancer Drug Discov. 8:53–65.
2013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Pardo LA and Stühmer W: The roles of K(+)
channels in cancer. Nat Rev Cancer. 14:39–48. 2014. View Article : Google Scholar : PubMed/NCBI
|
13
|
Innamaa A, Jackson L, Asher V, Van
Shalkwyk G, Warren A, Hay D, Bali A, Sowter H and Khan R:
Expression and prognostic significance of the oncogenic K2P
potassium channel KCNK9 (TASK-3) in ovarian carcinoma. Anticancer
Res. 33:1401–1408. 2013.PubMed/NCBI
|
14
|
Asher V, Khan R, Warren A, Shaw R,
Schalkwyk GV, Bali A and Sowter HM: The Eag potassium channel as a
new prognostic marker in ovarian cancer. Diagn Pathol. 5:782010.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Cicek MS, Koestler DC, Fridley BL, Kalli
KR, Armasu SM, Larson MC, Wang C, Winham SJ, Vierkant RA, Rider DN,
et al: Epigenome-wide ovarian cancer analysis identifies a
methylation profile differentiating clear-cell histology with
epigenetic silencing of the HERG K+ channel. Hum Mol
Genet. 22:3038–3047. 2013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Pillozzi S, Masselli M, De Lorenzo E,
Accordi B, Cilia E, Crociani O, Amedei A, Veltroni M, D'Amico M,
Basso G, et al: Chemotherapy resistance in acute lymphoblastic
leukemia requires hERG1 channels and is overcome by hERG1 blockers.
Blood. 117:902–914. 2011. View Article : Google Scholar : PubMed/NCBI
|
17
|
Köhler M, Hirschberg B, Bond CT, Kinzie
JM, Marrion NV, Maylie J and Adelman JP: Small-conductance,
calcium-activated potassium channels from mammalian brain. Science.
273:1709–1714. 1996. View Article : Google Scholar : PubMed/NCBI
|
18
|
Chantome A, Girault A, Potier M, Collin C,
Vaudin P, Pagès JC, Vandier C and Joulin V: KCa2.3
channel-dependent hyperpolarization increases melanoma cell
motility. Exp Cell Res. 315:3620–3630. 2009. View Article : Google Scholar : PubMed/NCBI
|
19
|
Potier M, Joulin V, Roger S, Besson P,
Jourdan ML, Leguennec JY, Bougnoux P and Vandier C: Identification
of SK3 channel as a new mediator of breast cancer cell migration.
Mol Cancer Ther. 5:2946–2953. 2006. View Article : Google Scholar : PubMed/NCBI
|
20
|
Jelassi B, Chantome A, Alcaraz-Pérez F,
Baroja-Mazo A, Cayuela ML, Pelegrin P, Surprenant A and Roger S:
P2X(7) receptor activation enhances SK3 channels- and cystein
cathepsin-dependent cancer cells invasiveness. Oncogene.
30:2108–2122. 2011. View Article : Google Scholar : PubMed/NCBI
|
21
|
Gueguinou M, Harnois T, Crottes D, Uguen
A, Deliot N, Gambade A, Chantôme A, Haelters JP, Jaffrès PA,
Jourdan ML, et al: SK3/TRPC1/Orai1 complex regulates SOCE-dependent
colon cancer cell migration: A novel opportunity to modulate
anti-EGFR mAb action by the alkyl-lipid Ohmline. Oncotarget.
7:36168–36184. 2016. View Article : Google Scholar : PubMed/NCBI
|
22
|
Li X, Pennisi A, Zhan F, Sawyer JR,
Shaughnessy JD and Yaccoby S: Establishment and exploitation of
hyperdiploid and non-hyperdiploid human myeloma cell lines. Br J
Haematol. 138:802–811. 2007. View Article : Google Scholar : PubMed/NCBI
|
23
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
24
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
25
|
Cancer Genome Atlas Research Network:
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
26
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
27
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
28
|
Gyorffy B, Lánczky A and Szállási Z:
Implementing an online tool for genome-wide validation of
survival-associated biomarkers in ovarian-cancer using microarray
data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.PubMed/NCBI
|
30
|
Jenssen TK, Laegreid A, Komorowski J and
Hovig E: A literature network of human genes for high-throughput
analysis of gene expression. Nat Genet. 28:21–28. 2001. View Article : Google Scholar : PubMed/NCBI
|
31
|
Mostafavi S, Ray D, Warde-Farley D,
Grouios C and Morris Q: GeneMANIA: A real-time multiple association
network integration algorithm for predicting gene function. Genome
Biol. 9 Suppl 1:S42008. View Article : Google Scholar : PubMed/NCBI
|
32
|
Warde-Farley D, Donaldson SL, Comes O,
Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT,
et al: The GeneMANIA prediction server: Biological network
integration for gene prioritization and predicting gene function.
Nucleic Acids Res. 38:W214–W220. 2010. View Article : Google Scholar : PubMed/NCBI
|
33
|
Lu TP, Lee CY, Tsai MH, Chiu YC, Hsiao CK,
Lai LC and Chuang EY: miRSystem: An integrated system for
characterizing enriched functions and pathways of microRNA targets.
PLoS One. 7:e423902012. View Article : Google Scholar : PubMed/NCBI
|
34
|
Hedditch EL, Gao B, Russell AJ, Lu Y,
Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J, et
al: ABCA transporter gene expression and poor outcome in epithelial
ovarian cancer. J Natl Cancer Inst. 106:pii: dju149. 2014.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin
F: Oncogenes associated with drug resistance in ovarian cancer. J
Cancer Res Clin Oncol. 141:381–395. 2015. View Article : Google Scholar : PubMed/NCBI
|
36
|
Yin F, Liu X, Li D, Wang Q, Zhang W and Li
L: Tumor suppressor genes associated with drug resistance in
ovarian cancer (review). Oncol Rep. 30:3–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
37
|
Yin F, Liu X, Li D, Wang Q, Zhang W and Li
L: Bioinformatic analysis of chemokine (C-C motif) ligand 21 and
SPARC-like protein 1 revealing their associations with drug
resistance in ovarian cancer. Int J Oncol. 42:1305–1316. 2013.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Yin F, Liu L, Liu X, Li G, Zheng L, Li D,
Wang Q, Zhang W and Li L: Downregulation of tumor suppressor gene
ribonuclease T2 and gametogenetin binding protein 2 is associated
with drug resistance in ovarian cancer. Oncol Rep. 32:362–372.
2014. View Article : Google Scholar : PubMed/NCBI
|
39
|
Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin
F: Upregulation of NEK2 is associated with drug resistance in
ovarian cancer. Oncol Rep. 31:745–754. 2014. View Article : Google Scholar : PubMed/NCBI
|
40
|
Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin
F: Downregulation of NEK11 is associated with drug resistance in
ovarian cancer. Int J Oncol. 45:1266–1274. 2014. View Article : Google Scholar : PubMed/NCBI
|
41
|
Liu X, Gao Y, Zhao B, Li X, Lu Y, Zhang J,
Li D, Li L and Yin F: Discovery of microarray-identified genes
associated with ovarian cancer progression. Int J Oncol.
46:2467–2478. 2015. View Article : Google Scholar : PubMed/NCBI
|
42
|
Liu X, Zou J, Su J, Lu Y, Zhang J, Li L
and Yin F: Downregulation of transient receptor potential cation
channel, subfamily C, member 1 contributes to drug resistance and
high histological grade in ovarian cancer. Int J Oncol. 48:243–252.
2016. View Article : Google Scholar : PubMed/NCBI
|
43
|
Sparks R, Lau WW and Tsang JS: Expanding
the immunology toolbox: Embracing public-data reuse and
crowdsourcing. Immunity. 45:1191–1204. 2016. View Article : Google Scholar : PubMed/NCBI
|
44
|
Grechkin M, Poon H and Howe B: Wide-Open:
Accelerating public data release by automating detection of overdue
datasets. PLoS Biol. 15:e20024772017. View Article : Google Scholar : PubMed/NCBI
|
45
|
Rung J and Brazma A: Reuse of public
genome-wide gene expression data. Nat Rev Genet. 14:89–99. 2013.
View Article : Google Scholar : PubMed/NCBI
|
46
|
Kannan L, Ramos M, Re A, El-Hachem N,
Safikhani Z, Gendoo DM, Davis S, Gomez-Cabrero D, Castelo R, Hansen
KD, et al: Public data and open source tools for multi-assay
genomic investigation of disease. Brief Bioinform. 17:603–615.
2016. View Article : Google Scholar : PubMed/NCBI
|
47
|
Sharan R, Ulitsky I and Shamir R:
Network-based prediction of protein function. Mol Syst Biol.
3:882007. View Article : Google Scholar : PubMed/NCBI
|
48
|
Shin SS, Park SS, Hwang B, Moon B, Kim WT,
Kim WJ and Moon SK: MicroRNA-892b influences proliferation,
migration and invasion of bladder cancer cells by mediating the
p19ARF/cyclin D1/CDK6 and Sp-1/MMP-9 pathways. Oncol Rep.
36:2313–2320. 2016. View Article : Google Scholar : PubMed/NCBI
|
49
|
Jiang L, Yu L, Zhang X, Lei F, Wang L, Liu
X, Wu S, Zhu J, Wu G, Cao L, et al: miR-892b silencing activates
NF-κB and promotes aggressiveness in breast cancer. Cancer Res.
76:1101–1111. 2016. View Article : Google Scholar : PubMed/NCBI
|
50
|
Lloyd KL, Cree IA and Savage RS:
Prediction of resistance to chemotherapy in ovarian cancer: A
systematic review. BMC Cancer. 15:1172015. View Article : Google Scholar : PubMed/NCBI
|
51
|
Emmons MF, Anreddy N, Cuevas J,
Steinberger K, Yang S, McLaughlin M, Silva A and Hazlehurst LA:
MTI-101 treatment inducing activation of Stim1 and TRPC1 expression
is a determinant of response in multiple myeloma. Sci Rep.
2:72017.
|